All In Biotech

Drug Trial Radar · NCT02194985

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease

Last checked: Nov 19, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Mar 14, 2015

Primary completion

Oct 23, 2019

Study completion Oct 23, 2019

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.

Conditions

  • Fabry Disease

Interventions

  • migalastat HCl 150 mgDrug

    Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants Experiencing Adverse Events (AEs)Time frame: Day 1 after first dose to approximately 30 days after last treatment, median duration of 3.1 years

Locations

28 sites in 15 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Atlanta, Georgia

  • Clinical Study Site

    Kansas City, Kansas

  • Clinical Study Site

    Grand Rapids, Michigan

  • Clinical Study Site

    New York, New York

  • Clinical Study Site

    Portland, Oregon

  • Clinical Study Site

    Dallas, Texas

  • Clinical Study Site

    Fairfax, Virginia

  • Clinical Study Site

    Pilar, Argentina

  • Clinical Study Site

    Adelaide, Australia

  • Clinical Study Site

    Parkville, Australia

  • Clinical Study Site

    Vienna, Austria

  • Clinical Study Site

    Edegem, Belgium

  • Clinical Study Site

    Porto Alegre, Brazil

  • Clinical Study Site

    Montreal, Quebec, Canada

  • Clinical Study Site

    Copenhagen, Denmark

  • Clinical Study Site

    Cairo, Egypt

  • Clinical Study Site

    Garches, France

  • Clinical Study Site

    Lille, France

  • Clinical Study Site

    Florence, Italy

  • Clinical Study Site

    Roma, Italy

  • Clinical Study Site

    Niigata, Japan

  • Clinical Study Site

    Osaka, Japan

  • Clinical Study Site

    Tokyo, Japan

  • Clinical Study Site

    Suita, Osaka, Japan

  • Clinical Study Site

    Barcelona, Spain

  • Clinical Study Site

    Ankara, Turkey (Türkiye)

  • Clinical Study Site

    London, United Kingdom

  • Clinical Study Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.